OCT 10, 2017 09:00 AM PDT

WEBINAR: Automated single cell dissociation of primary tumors and patient-derived xenografts

Sponsored by: Miltenyi Biotec
Speakers
  • Assistant Laboratory Member, Memorial Sloan Kettering Cancer Center Medicine
    Biography
      My lab focuses on development of new patient derived xenograft models and experimental lung cancer therapeutics. During my career I have developed a wide range of skills in both laboratory based and computational research. My hybrid skill set positions me well to operate at the interface between the world of the wet lab and that of the high-performance computing cluster. My research has focused on the genetic and epigenetic landscapes of small cell lung cancer, therapeutic targeting of the DLL3, and development of oncolytic viral therapies. In addition to my primary research focus, I established and currently oversee an active program in patient-derived xenograft development and characterization. Through this program I have developed a series of best practices for genetic characterization of human xenografts grown in mice and biomarker validation in PDX.

    Abstract:

    DATE: October 10, 2017
    TIME: 9:00AM PDT

    Patient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line xenografts, which are established from suspensions of cultured cells, PDX are maintained entirely in vivo. While exclusive in vivo maintenance is the primary advantage of PDX as a model for cancer, the practice introduces unique challenges and potential pitfalls to working with PDX as a model for cancer. Perhaps the most significant challenge to working with PDX is the need to disaggregate solid tumors prior to their use in downstream applications such as flow cytometry, immunomagnetic enrichment, single-cell sequencing or the establishment of cohorts for therapeutic trials. This webinar will discuss our experience with automated single cell dissociation of primary tumors and patient-derived xenografts as well as compatibility with downstream applications.

     

    Learning Objectives:

    • Advantages and challenges associate with using PDX models for cancer research
    • Solid tumor dissociation methods compatible for downstream single-cell applications, such as flow cytometry, immunomagnetic enrichment and single-cell sequencing

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    NOV 18, 2019 07:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JAN 23, 2020 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JAN 23, 2020 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: TIME: adadf adfadf...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    FEB 25, 2020 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 25, 2020 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 09:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 09:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources